| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York 10461
In the human lung carcinoma cell line A549, Taxol (20 nM)
causes a decreased electrophoretic mobility of the 66-kDa Shc isoform
(p66shc), beginning 4 h after drug exposure, and reaching a
maximum at 918 h. No shift was observed for the 52- and 46-kDa
isoforms of Shc. The electrophoretic mobility shift of p66shc caused by
Taxol is not the result of tyrosine phosphorylation, and there is no
indication of a Shc/Grb2 complex in Taxol-treated A549 cells. This
modification is blocked by the serine/threonine protein phosphatase 2A.
In vivo 32P-labeling and subsequent
phosphoamino acid analysis of p66shc indicated that both the original
and the shifted p66shc were predominantly serine phosphorylated.
Cyanogen bromide digestion of p66shc produced a phosphorylated
fragment with an apparent molecular weight of
7.9 kDa from the
untreated cells and two phosphorylated fragments, of
7.9 and
9.6
kDa, from the Taxol-treated cells. The domain of Taxol-induced serine
phosphorylation is thought to be in the cyanogen bromide
fragment containing residues 265. The Taxol-induced electrophoretic
mobility shift of p66shc was inhibited by the protein synthesis
inhibitor, cycloheximide, but not by the mitogen-activated and
extracellular signal-regulated protein kinase kinase (MEK)
inhibitor, PD98059. This mobility shift did not occur in
Taxol-resistant A549-T12 cells treated with 20 nM Taxol. In
addition to Taxol, other microtubule-interacting drugs caused a
decreased electrophoretic mobility of p66shc. This Taxol-mediated
serine phosphorylation seen in p66shc may result from a MEK-independent
signaling pathway that is activated in cells that have a prolonged or
abnormal mitotic phase of the cell cycle and may play a role in
signaling events that lead to cell death.
This article has been cited by other articles:
![]() |
Y. Hu, X. Wang, L. Zeng, D.-Y. Cai, K. Sabapathy, S. P. Goff, E. J. Firpo, and B. Li ERK Phosphorylates p66shcA on Ser36 and Subsequently Regulates p27kip1 Expression via the Akt-FOXO3a Pathway: Implication of p27kip1 in Cell Response to Oxidative Stress Mol. Biol. Cell, August 1, 2005; 16(8): 3705 - 3718. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. W. Smith, D. D. Norton, M. Gorospe, H. Jiang, S. Nemoto, N. J. Holbrook, T. Finkel, and J. W. Kusiak Phosphorylation of p66Shc and forkhead proteins mediates A{beta} toxicity J. Cell Biol., April 25, 2005; 169(2): 331 - 339. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Pagnin, G. Fadini, R. de Toni, A. Tiengo, L. Calo, and A. Avogaro Diabetes Induces p66shc Gene Expression in Human Peripheral Blood Mononuclear Cells: Relationship to Oxidative Stress J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1130 - 1136. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Tinley, D. A. Randall-Hlubek, R. M. Leal, E. M. Jackson, J. W. Cessac, J. C. Quada Jr., T. K. Hemscheidt, and S. L. Mooberry Taccalonolides E and A: Plant-derived Steroids with Microtubule-stabilizing Activity Cancer Res., June 15, 2003; 63(12): 3211 - 3220. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lee, W. Yang, K.-H. Lan, S. Sellappan, K. Klos, G. Hortobagyi, M.-C. Hung, and D. Yu Enhanced Sensitization to Taxol-induced Apoptosis by Herceptin Pretreatment in ErbB2-overexpressing Breast Cancer Cells Cancer Res., October 15, 2002; 62(20): 5703 - 5710. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Faisal, M. El-Shemerly, D. Hess, and Y. Nagamine Serine/Threonine Phosphorylation of ShcA. REGULATION OF PROTEIN-TYROSINE PHOSPHATASE-PEST BINDING AND INVOLVEMENT IN INSULIN SIGNALING J. Biol. Chem., August 9, 2002; 277(33): 30144 - 30152. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Le, T. J. Connors, and A. C. Maroney c-Jun N-terminal Kinase Specifically Phosphorylates p66ShcA at Serine 36 in Response to Ultraviolet Irradiation J. Biol. Chem., December 14, 2001; 276(51): 48332 - 48336. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. McDaid and S. B. Horwitz Selective Potentiation of Paclitaxel (Taxol)-Induced Cell Death by Mitogen-Activated Protein Kinase Kinase Inhibition in Human Cancer Cell Lines Mol. Pharmacol., August 1, 2001; 60(2): 290 - 301. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-i. Okano and A. K. Rustgi Paclitaxel Induces Prolonged Activation of the Ras/MEK/ERK Pathway Independently of Activating the Programmed Cell Death Machinery J. Biol. Chem., May 25, 2001; 276(22): 19555 - 19564. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |